Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

Autor: Luisa Castro-Laria, Ana M. Sánchez-Migallón, David Busquets, Ana Echarri, Maria Esteve, Federico Argüelles-Arias, R. Vicente, José María Huguet, María Dolores Martín-Arranz, D Ceballos, Francesc Casellas, Jordina Llaó, for Rapida trial investigators, M Navarro-Llavat, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Santiago García-López, José Miguel Boudet, Gema Díaz

Publikováno v: Gastroenterología y Hepatología (English Edition). 45:165-176

No studies evaluating the rapidity of response to biological therapies are available for Crohn's disease (CD). The aim of this study was to evaluate rapidity of onset of clinical response and impact on quality of life (QoL) of adalimumab therapy in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d881354db875481448ab555e85c9c9
https://doi.org/10.1016/j.gastre.2021.04.007

P513 Prospective study on patients’ satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease

Autor: M Navarro Llavat, O García-Bosch, J Castro-Poceiro, A Bargalló García, D Ruiz Arroyo, Y Navas Bravo, E Erice Muñoz, D Barquero Declara, A Mata Bilbao, M Martín Llahí, X Ariza Solé, C Hernández Ballesteros, A Juan Juan, K Bustamante Robles, C Berbel Comas, A Blasco Pelicano, M Albareda Riera, E Domènech Morral

Publikováno v: Journal of Crohn's and Colitis. 17:i642-i642

Background Corticosteroids (Cs) remain the first-line therapy for moderate-to-severe flares in patients with inflammatory bowel disease (IBD), both Crohn’s disease (CD) and ulcerative colitis (UC). On the other hand, their use has been associated t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a216e247f7d265b51d3d9c83afdb31f
https://doi.org/10.1093/ecco-jcc/jjac190.0643

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Autor: Laura Ramos, Patricia Ramirez de la Piscina, Carlos Taxonera, Luisa de Castro, Belén Beltrán, Fernando Bermejo, Rosa Eva Madrigal, E Sesé, Fernando Gomollón, Alfredo J. Lucendo, Jesús Barrio, Xavier Calvet, Joaquín Hinojosa, Cristina Rodríguez, Gloria Esther Rodriguez, Carmen Muñoz, Ana Gutiérrez, Mara Charro, Eugeni Domènech, David Monfort, Esther Garcia-Planella, M F García-Sepulcre, José María Huguet, María Chaparro, Javier P. Gisbert, R. Pajares, José Lázaro Pérez-Calle, Montserrat Rivero, Jordi Guardiola, Luis Fernández-Salazar, Federico Argüelles-Arias, Xavier Aldeguer, Agueda Abad, Jordina Llaó, Guillermo Alcain, Pedro Almela, Sabino Riestra, Olga Merino, M Navarro-Llavat, Luis Bujanda, Manuel Domínguez-Cajal, Maria Esteve, Sam Khorrami, María Dolores Martín-Arranz, Lucía Márquez, Antonio Roman, María Isabel Vera, Rufo Lorente, Antonio García-Herola, Beatriz Sicilia, A Rodríguez-Pérez, Pilar Varela, Santiago García-López, Pilar Martínez-Montiel, Miguel Minguez, Manuel Van Domselaar, María José Casanova, Patricia Romero, Iago Rodríguez-Lago, Elena Ricart, Eva Iglesias

Publikováno v: INFLAMMATORY BOWEL DISEASES
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
JOURNAL OF CROHNS & COLITIS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Inflammatory Bowel Diseases
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Dipòsit Digital de la UB
Universidad de Barcelona
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza

Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86615e3320311a1a111063c6f1675fc6
https://fundanet.fihgu.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1634

P371 The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study

Autor: E Domènech Moral PhD, J Llaó, M Mañosa, E Martín-Arranz, Y Zabana, M Navarro-Llavat, E Garcia-Planella, D Busquets, J R Pineda, D Monfort, A Gutiérrez, F J García-Alonso, L A Menchén, A Villoria

Publikováno v: Journal of Crohn's and Colitis. 16:i374-i374

Background Oral corticosteroids remain the treatment of choice for moderately active flares of ulcerative colitis (UC). In early controlled studies, oral corticosteroids achieved clinical remission rates of, 30–60% at, 30 days. Some small prospecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f804cccd0652d002444ef19455ff2610
https://doi.org/10.1093/ecco-jcc/jjab232.498